|N-(4-氯苯基)-5,5-二氟-1-(3-(呋喃-2-基)苯甲酰基)哌啶-3-甲酰胺|CsnPharm

CAS No.: 1922098-69-8

CCG-222740 Catalog No. CSN25251

Synonyms: CCG-222740

CCG-222740 is a Rho/MRTF pathway inhibitor. It decreases the activation of stellate cells in vitro and in vivo, by reducing the levels of alpha smooth muscle actin (α-SMA) expression. It also modulates inflammatory components of the pancreas in KC mice (LSL-KrasG12D/+; Pdx-1-Cre) stimulated with caerulein.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述In fibroblasts, the Rho/myocardin-related transcription factor (MRTF) pathway has classically been associated with cell contractility, and CAFs (Cancer associated fibroblasts) rely on this pathway to generate tracks for cancer cell migration. This pathway is implicated in the hyper-activation of fibroblasts in fibrotic diseases and the activation of pancreatic stellate cells. CCG-222740, a small molecule, is designed as a Rho/MRTF pathway inhibitor. PSCs (Pancreatic stellate cells), isolated as previously described from the pancreas of wild type C57BL/6 mice, were cultured for 3 days to achive confluence and then treated with CCG-222740 for 6 days. Treatment with 1 μM of CCG-222740 significantly (p < 0.05) reduced the levels of α-SMA (α smooth muscle actin; a marker for stellate cell activation) and collagen 2 A levels in the PSCs. CAFs isolated from a mouse pancreatic tumor induced by a Kras mutation were treated with several concentrations of CCG-222740 for 72 hours. This treatment decreased cell viability of CAFs, with an IC₅₀ of ~10 μM, as measured by the MTT assay. CCG-222740 also had growth inhibitory effects on human and mouse pancreatic cancer cells, inducing growth arrest at similar concentrations as the CAFs. Moreover, CCG-222740 increased the protein levels of p27 and decreased cyclin D1, while the levels of collagens I, 2a and IV, as well as α-SMA in the CAFs were decreased after treatment with CCG-222740 for 72 hours. In vivo, CCG-222740 (100 mg/kg daily) by oral gavage significantly reduced α-SMA levels in the pancreas of caerulein-stimulated KC mice (p < 0.05)^[1].
参考文献

[1] Leal AS, Misek SA, Lisabeth EM, Neubig RR, Liby KT. The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras^G12D; Pdx1-Cre (KC) mice. Sci Rep. 2019;9(1):7072. Published 2019 May 8

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.2479 mL
- 11.2395 mL
- 22.4791 mL
- 5 mM
- 0.4496 mL
- 2.2479 mL
- 4.4958 mL
- 10 mM
- 0.2248 mL
- 1.1240 mL
- 2.2479 mL

技术信息

CAS号

1922098-69-8

储存条件

粉末: Sealed in dry,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C23H19ClF2N2O3

运输

蓝冰

分子量

444.86

别名

CCG-222740

溶解度

DMSO	89.0 mg/mL (200.1 mM)
Water	Insoluble
Ethanol	89.0 mg/mL (200.1 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

CCG-222740 Catalog No. CSN25251

靶点选择性

请登录您的专属账户

确认信息